{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T05:10:02Z","timestamp":1751778602426,"version":"3.41.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"DOI":"10.7759\/cureus.87356","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:44:18Z","timestamp":1751777058000},"source":"Crossref","is-referenced-by-count":0,"title":["Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function"],"prefix":"10.7759","author":[{"given":"Akshita","family":"Suleria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakshi","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khanij","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mason T","family":"Stoltzfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhupinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanveer","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00358","article-title":"Psychedelics and immunomodulation: novel approaches and therapeutic opportunities","volume":"6","author":"Szabo A","year":"2015","unstructured":"Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Front Immunol. 2015, 6:358. 10.3389\/fimmu.2015.00358","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93787-4","article-title":"Associations between lifetime classic psychedelic use and cardiometabolic diseases","volume":"11","author":"Simonsson O","year":"2021","unstructured":"Simonsson O, Osika W, Carhart-Harris R, Hendricks PS. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep. 2021, 11:14427. 10.1038\/s41598-021-93787-4","journal-title":"Sci Rep"},{"key":"ref3","unstructured":"National Center for Biotechnology Information, PubChem.  Compound summary for CID 5761, lysergide. (2025). Accessed: Jauary 19, 2025: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lysergide."},{"key":"ref4","unstructured":"National Drug Intelligence Center. LSD fast facts. (2006). Accessed: August 17, 2023: https:\/\/www.justice.gov\/archive\/ndic\/pubs4\/4260\/index.htm."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT(1A), D(2) and TAAR(1) receptors","volume":"113","author":"De Gregorio D","year":"2016","unstructured":"De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R, Maione S, Comai S, Gobbi G. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT(1A), D(2) and TAAR(1) receptors. Pharmacol Res. 2016, 113:81-91. 10.1016\/j.phrs.2016.08.022","journal-title":"Pharmacol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2018.01.006","article-title":"Is LSD toxic?","volume":"284","author":"Nichols DE","year":"2018","unstructured":"Nichols DE, Grob CS. Is LSD toxic?. Forensic Sci Int. 2018, 284:141-5. 10.1016\/j.forsciint.2018.01.006","journal-title":"Forensic Sci Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/heart.83.6.627","article-title":"Recreational drug misuse: issues for the cardiologist","volume":"83","author":"Ghuran A","year":"2000","unstructured":"Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000, 83:627-33. 10.1136\/heart.83.6.627","journal-title":"Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser P","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014, 202:513-20. 10.1097\/NMD.0000000000000113","journal-title":"J Nerv Ment Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2057","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants","volume":"109","author":"Holze F","year":"2021","unstructured":"Holze F, Liechti ME, Hutten NR, et al.. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin Pharmacol Ther. 2021, 109:658-66. 10.1002\/cpt.2057","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0013","article-title":"Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry","volume":"1","author":"Aday JS","year":"2023","unstructured":"Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS. Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry. Psychedelic Med (New Rochelle). 2023, 1:150-65. 10.1089\/psymed.2023.0013","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze F","year":"2023","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023, 93:215-23. 10.1016\/j.biopsych.2022.08.025","journal-title":"Biol Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen MK","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, et al.. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019, 44:1328-34. 10.1038\/s41386-019-0324-9","journal-title":"Neuropsychopharmacology"},{"key":"ref13","article-title":"Lysergic acid diethylamide (LSD)","author":"Hwang KAJ","year":"2023","unstructured":"Hwang KAJ, Saadabadi A. Lysergic acid diethylamide (LSD). StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie T","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008, 14:295-314. 10.1111\/j.1755-5949.2008.00059.x","journal-title":"CNS Neurosci Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.129.1049","article-title":"Pharmacological studies on responsiveness of 5-hydroxytryptamine in overcoming perioperative spasm of coronary artery bypass graft [Article in Japanese]","volume":"129","author":"Tanaka N","year":"2009","unstructured":"Tanaka N. Pharmacological studies on responsiveness of 5-hydroxytryptamine in overcoming perioperative spasm of coronary artery bypass graft [Article in Japanese]. Yakugaku Zasshi. 2009, 129:1049-53. 10.1248\/yakushi.129.1049","journal-title":"Yakugaku Zasshi"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(01)00169-3","article-title":"Multiplicity of mechanisms of serotonin receptor signal transduction","volume":"92","author":"Raymond JR","year":"2001","unstructured":"Raymond JR, Mukhin YV, Gelasco A, et al.. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther. 2001, 92:179-212. 10.1016\/s0163-7258(01)00169-3","journal-title":"Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2165\/11589340-000000000-00000","article-title":"Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients","volume":"28","author":"de Abajo FJ","year":"2011","unstructured":"de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011, 28:345-67. 10.2165\/11589340-000000000-00000","journal-title":"Drugs Aging"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2004.tb00130.x","article-title":"Therapeutic potentials of sarpogrelate in cardiovascular disease","volume":"22","author":"Saini HK","year":"2004","unstructured":"Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev. 2004, 22:27-54. 10.1111\/j.1527-3466.2004.tb00130.x","journal-title":"Cardiovasc Drug Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158794","article-title":"A novel antibody targeting the second extracellular loop of the serotonin 5-HT2A receptor inhibits platelet function","volume":"23","author":"Ramirez JE","year":"2022","unstructured":"Ramirez JE, Alarabi AB, Khasawneh FT, Alshbool FZ. A novel antibody targeting the second extracellular loop of the serotonin 5-HT2A receptor inhibits platelet function. Int J Mol Sci. 2022, 23:8794. 10.3390\/ijms23158794","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban JD","year":"2007","unstructured":"Urban JD, Clarke WP, von Zastrow M, et al.. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007, 320:1-13. 10.1124\/jpet.106.104463","journal-title":"J Pharmacol Exp Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2248883","article-title":"Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents","volume":"22","author":"McIntyre RS","year":"2023","unstructured":"McIntyre RS. Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf. 2023, 22:881-3. 10.1080\/14740338.2023.2248883","journal-title":"Expert Opin Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231225609","article-title":"Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins","volume":"38","author":"Rouaud A","year":"2024","unstructured":"Rouaud A, Calder AE, Hasler G. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. J Psychopharmacol. 2024, 38:217-24. 10.1177\/02698811231225609","journal-title":"J Psychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231190865","article-title":"The risk of chronic psychedelic and MDMA microdosing for valvular heart disease","volume":"37","author":"Tagen M","year":"2023","unstructured":"Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. J Psychopharmacol. 2023, 37:876-90. 10.1177\/02698811231190865","journal-title":"J Psychopharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman D","year":"2019","unstructured":"Furman D, Campisi J, Verdin E, et al.. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019, 25:1822-32. 10.1038\/s41591-019-0675-0","journal-title":"Nat Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1042440","article-title":"Classic psychedelics do not affect T cell and monocyte immune responses","volume":"14","author":"Rudin D","year":"2023","unstructured":"Rudin D, Areesanan A, Liechti ME, Gr\u00fcndemann C. Classic psychedelics do not affect T cell and monocyte immune responses. Front Psychiatry. 2023, 14:1042440. 10.3389\/fpsyt.2023.1042440","journal-title":"Front Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0513-9","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects","volume":"56","author":"Dolder PC","year":"2017","unstructured":"Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 2017, 56:1219-30. 10.1007\/s40262-017-0513-9","journal-title":"Clin Pharmacokinet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxg027","article-title":"Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors","volume":"15","author":"Clo\u00ebz-Tayarani I","year":"2003","unstructured":"Clo\u00ebz-Tayarani I, Petit-Bertron AF, Venters HD, Cavaillon JM. Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors. Int Immunol. 2003, 15:233-40. 10.1093\/intimm\/dxg027","journal-title":"Int Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075426","article-title":"Serotonin 5-HT2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo","volume":"8","author":"Nau F Jr","year":"2013","unstructured":"Nau F Jr, Yu B, Martin D, Nichols CD. Serotonin 5-HT2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo. PLoS One. 2013, 8:e75426. 10.1371\/journal.pone.0075426","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/psyp.13822","article-title":"LSD and ketanserin and their impact on the human autonomic nervous system","volume":"58","author":"Olbrich S","year":"2021","unstructured":"Olbrich S, Preller KH, Vollenweider FX. LSD and ketanserin and their impact on the human autonomic nervous system. Psychophysiology. 2021, 58:e13822. 10.1111\/psyp.13822","journal-title":"Psychophysiology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016, 68:264-355. 10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0367-7","article-title":"Cerebrovascular and cardiovascular diseases caused by drugs of abuse","volume":"43","author":"Akasaki Y","year":"2020","unstructured":"Akasaki Y, Ohishi M. Cerebrovascular and cardiovascular diseases caused by drugs of abuse. Hypertens Res. 2020, 43:363-71. 10.1038\/s41440-019-0367-7","journal-title":"Hypertens Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin SJ","year":"2018","unstructured":"Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology. 2018, 142:7-19. 10.1016\/j.neuropharm.2018.02.018","journal-title":"Neuropharmacology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16715","article-title":"Association between lifetime classic psychedelic use and hypertension in the past year","volume":"77","author":"Simonsson O","year":"2021","unstructured":"Simonsson O, Hendricks PS, Carhart-Harris R, Kettner H, Osika W. Association between lifetime classic psychedelic use and hypertension in the past year. Hypertension. 2021, 77:1510-6. 10.1161\/HYPERTENSIONAHA.120.16715","journal-title":"Hypertension"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5551\/jat.58305","article-title":"5-HT2A receptor and 5-HT degradation play a crucial role in atherosclerosis by modulating macrophage foam cell formation, vascular endothelial cell inflammation, and hepatic steatosis","volume":"29","author":"Ma Y","year":"2022","unstructured":"Ma Y, Liang X, Li C, et al.. 5-HT2A receptor and 5-HT degradation play a crucial role in atherosclerosis by modulating macrophage foam cell formation, vascular endothelial cell inflammation, and hepatic steatosis. J Atheroscler Thromb. 2022, 29:322-36. 10.5551\/jat.58305","journal-title":"J Atheroscler Thromb"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12374","article-title":"Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects","volume":"28","author":"Strajhar P","year":"2016","unstructured":"Strajhar P, Schmid Y, Liakoni E, et al.. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016, 28:12374. 10.1111\/jne.12374","journal-title":"J Neuroendocrinol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05978-6","article-title":"Safety pharmacology of acute LSD administration in healthy subjects","volume":"239","author":"Holze F","year":"2022","unstructured":"Holze F, Caluori TV, Vizeli P, Liechti ME. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology (Berl). 2022, 239:1893-905. 10.1007\/s00213-021-05978-6","journal-title":"Psychopharmacology (Berl)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2825","article-title":"The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers","volume":"37","author":"Li H","year":"2022","unstructured":"Li H, Zhong Y, Yang S, et al.. The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers. Hum Psychopharmacol. 2022, 37:e2825. 10.1002\/hup.2825","journal-title":"Hum Psychopharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson T","year":"2019","unstructured":"Anderson T, Petranker R, Christopher A, et al.. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J. 2019, 16:43. 10.1186\/s12954-019-0308-4","journal-title":"Harm Reduct J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000467","article-title":"How do psychedelics work?","volume":"32","author":"Carhart-Harris RL","year":"2019","unstructured":"Carhart-Harris RL. How do psychedelics work?. Curr Opin Psychiatry. 2019, 32:16-21. 10.1097\/YCO.0000000000000467","journal-title":"Curr Opin Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211008554","article-title":"Psychedelics and health behaviour change","volume":"36","author":"Teixeira PJ","year":"2022","unstructured":"Teixeira PJ, Johnson MW, Timmermann C, et al.. Psychedelics and health behaviour change. J Psychopharmacol. 2022, 36:12-9. 10.1177\/02698811211008554","journal-title":"J Psychopharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: a placebo-controlled, dose-response study","volume":"27","author":"de Wit H","year":"2022","unstructured":"de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: a placebo-controlled, dose-response study. Addict Biol. 2022, 27:e13143. 10.1111\/adb.13143","journal-title":"Addict Biol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114003","article-title":"Dexfenfluramine and pergolide cause heart valve disease via valve metabolic reprogramming and ongoing matrix remodeling","volume":"21","author":"Oury C","year":"2020","unstructured":"Oury C, Mar\u00e9chal P, Donis N, et al.. Dexfenfluramine and pergolide cause heart valve disease via valve metabolic reprogramming and ongoing matrix remodeling. Int J Mol Sci. 2020, 21:4003. 10.3390\/ijms21114003","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.05.008","article-title":"Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy","volume":"19","author":"Raval MV","year":"2008","unstructured":"Raval MV, Gaba RC, Brown K, Sato KT, Eskandari MK. Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy. J Vasc Interv Radiol. 2008, 19:1227-30. 10.1016\/j.jvir.2008.05.008","journal-title":"J Vasc Interv Radiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.5.2.213","article-title":"Carotid artery occlusion following ingestion of LSD","volume":"5","author":"Lieberman AN","year":"1974","unstructured":"Lieberman AN, Bloom W, Kishore PS, Lin JP. Carotid artery occlusion following ingestion of LSD. Stroke. 1974, 5:213-5. 10.1161\/01.str.5.2.213","journal-title":"Stroke"},{"key":"ref45","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1971.00310140118016","article-title":"Carotid artery obstruction following LSD capsule ingestion","volume":"127","author":"Sobel J","year":"1971","unstructured":"Sobel J, Espinas OE, Friedman SA. Carotid artery obstruction following LSD capsule ingestion. Arch Intern Med. 1971, 127:290-1.","journal-title":"Arch Intern Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaa145","article-title":"Severe neurological sequelae after a recreational dose of LSD","volume":"45","author":"Aaker\u00f8y R","year":"2021","unstructured":"Aaker\u00f8y R, Brede WR, St\u00f8len SB, et al.. Severe neurological sequelae after a recreational dose of LSD. J Anal Toxicol. 2021, 45:e1-3. 10.1093\/jat\/bkaa145","journal-title":"J Anal Toxicol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.1957183","article-title":"Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey","volume":"54","author":"Barnett BS","year":"2022","unstructured":"Barnett BS, Beaussant Y, King F 4th, Doblin R. Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey. J Psychoactive Drugs. 2022, 54:269-77. 10.1080\/02791072.2021.1957183","journal-title":"J Psychoactive Drugs"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes JJ","year":"2019","unstructured":"Fuentes JJ, Fonseca F, Elices M, Farr\u00e9 M, Torrens M. Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psychiatry. 2019, 10:943. 10.3389\/fpsyt.2019.00943","journal-title":"Front Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332515-lysergic-acid-diethylamide-lsd-and-the-heart-exploring-the-potential-impacts-of-lsd-on-cardiovascular-function","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:44:19Z","timestamp":1751777059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332515-lysergic-acid-diethylamide-lsd-and-the-heart-exploring-the-potential-impacts-of-lsd-on-cardiovascular-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.87356","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}